Morse Asset Management Inc increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 27.3% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 12,210 shares of the biotechnology company’s stock after buying an additional 2,621 shares during the quarter. Morse Asset Management Inc’s holdings in Ascendis Pharma A/S were worth $2,782,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the business. Perceptive Advisors LLC raised its position in Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock worth $350,282,000 after buying an additional 450,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in Ascendis Pharma A/S during the 1st quarter valued at about $26,837,000. Troluce Capital Advisors LLC bought a new position in Ascendis Pharma A/S during the 1st quarter valued at about $22,782,000. Sapient Capital LLC purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $24,581,000. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Ascendis Pharma A/S by 68.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock valued at $60,053,000 after acquiring an additional 91,822 shares during the last quarter.
Ascendis Pharma A/S Stock Performance
Shares of ASND stock opened at $275.39 on Monday. Ascendis Pharma A/S has a 1 year low of $188.08 and a 1 year high of $282.15. The firm has a fifty day moving average price of $242.67 and a 200-day moving average price of $239.83. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.89 and a quick ratio of 2.29. The company has a market cap of $17.18 billion, a price-to-earnings ratio of 18.00 and a beta of 0.40.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.47% and a net margin of 73.26%. The company had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. As a group, equities analysts predict that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.
Ascendis Pharma A/S News Roundup
Investors following ASND have been watching these news items:
- Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
- Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
- Negative Sentiment: Employee warrants may cause modest dilution. Ascendis granted 28,030 employee warrants, creating a potential increase in shares outstanding if exercised. Read More.
Wall Street Analysts Forecast Growth
ASND has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their price target on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Raymond James Financial reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Friday. Morgan Stanley lowered their price objective on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 1st. KeyCorp set a $330.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday. Finally, Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $326.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday. Nineteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $313.52.
View Our Latest Stock Analysis on ASND
Insider Buying and Selling
In related news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president directly owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 40.00% of the company’s stock.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Recommended Stories
- Five stocks we like better than Ascendis Pharma A/S
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
